Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Current Investments (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Cash & Current Investments for 6 consecutive years, with $147.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments fell 35.46% to $147.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $147.3 million, a 35.46% decrease, with the full-year FY2024 number at $209.5 million, down 36.28% from a year prior.
  • Cash & Current Investments was $147.3 million for Q3 2025 at Caribou Biosciences, down from $183.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $435.3 million in Q3 2021 to a low of $129.5 million in Q2 2021.
  • A 5-year average of $270.2 million and a median of $260.4 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 2255.87% in 2021, then tumbled 36.28% in 2024.
  • Caribou Biosciences' Cash & Current Investments stood at $375.8 million in 2021, then tumbled by 34.1% to $247.7 million in 2022, then skyrocketed by 32.77% to $328.8 million in 2023, then crashed by 36.28% to $209.5 million in 2024, then fell by 29.72% to $147.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Cash & Current Investments are $147.3 million (Q3 2025), $183.9 million (Q2 2025), and $208.5 million (Q1 2025).